Trials / Recruiting
RecruitingNCT07226427
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Stemline Therapeutics, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEN2501 | Oral tablet |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2027-12-02
- Completion
- 2028-06-02
- First posted
- 2025-11-10
- Last updated
- 2025-11-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07226427. Inclusion in this directory is not an endorsement.